Compass Therapeutics, Inc. short interest in 2026
In 2026, Compass Therapeutics, Inc.'s disclosed short interest ran from 12.93% of shares outstanding on 15 Jan 2026 to 23.13% on 15 Sep 2026, a change of +10.20 percentage points. The year's high was 23.13% on 15 Sep 2026 and its low 12.33% on 30 Jan 2026, averaging 17.46% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.62 days on 31 Jul 2026. Full history: Compass Therapeutics, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 12.93% (15 Jan 2026)
- End of year
- 23.13% (15 Sep 2026)
- Change
- +10.20 pp
- High
- 23.13% (15 Sep 2026)
- Low
- 12.33% (30 Jan 2026)
- Average
- 17.46%
- Highest days to cover
- 17.62 (31 Jul 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 12.93% | 7.80 | results (8-K) |
| 30 Jan 2026 | 12.33% | 9.88 | |
| 13 Feb 2026 | 12.57% | 11.30 | |
| 27 Feb 2026 | 12.94% | 12.27 | |
| 13 Mar 2026 | 13.39% | 11.82 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 14.69% | 12.05 | |
| 15 Apr 2026 | 14.66% | 9.43 | |
| 30 Apr 2026 | 16.89% | 1.35 | |
| 15 May 2026 | 17.23% | 4.07 | 10-Q filed, results (8-K) |
| 29 May 2026 | 18.47% | 6.41 | |
| 15 Jun 2026 | 18.05% | 9.48 | |
| 30 Jun 2026 | 20.62% | 8.89 | |
| 15 Jul 2026 | 21.82% | 15.67 | |
| 31 Jul 2026 | 22.14% | 17.62 | |
| 14 Aug 2026 | 22.32% | 9.78 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 22.65% | 17.26 | |
| 15 Sep 2026 | 23.13% | 15.99 |
See also: Compass Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.